Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Coagulation01:09

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Introduction to Hemostasis01:05

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neoplasm-induced bleeding in inherited, heterozygous FXIII-A deficiency.

Hamostaseologie·2015
Same author

Strong association of variants around FOXE1 and orofacial clefting.

Journal of dental research·2014
Same author

[Anticoagulation].

Medizinische Klinik, Intensivmedizin und Notfallmedizin·2013
Same author

In vitro characterization of recombinant factor VIII concentrates reveals significant differences in protein content, activity and thrombin activation profile.

Haemophilia : the official journal of the World Federation of Hemophilia·2012
Same author

Monitoring of plasma levels of activated protein C using a clinically applicable oligonucleotide-based enzyme capture assay.

Journal of thrombosis and haemostasis : JTH·2012
Same author

Haemostasis management of massive bleeding.

Hamostaseologie·2011

Related Experiment Video

Updated: May 27, 2026

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

Aptamer-based modulation of blood coagulation.

G Mayer1, F Rohrbach, B Pötzsch

  • 1University of Bonn, Life & Medical Sciences Institute, Bonn, Germany. gmayer@uni-bonn.de

Hamostaseologie
|November 9, 2011
PubMed
Summary

Nucleic acid aptamers offer a promising avenue for anticoagulant drug development by targeting key proteins in the coagulation cascade. This review highlights recent advancements in aptamer design and evaluation for therapeutic applications.

More Related Videos

Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)
04:56

Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)

Published on: August 4, 2023

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Related Experiment Videos

Last Updated: May 27, 2026

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)
04:56

Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)

Published on: August 4, 2023

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Aptamers are single-stranded DNA or RNA molecules selected for specific binding to targets.
  • Their unique 3D structures enable selective interaction with various molecules, including coagulation proteins.
  • Anticoagulant drug development is a key area of aptamer research.

Purpose of the Study:

  • To review recent progress in the design and evaluation of aptamers for anticoagulant therapy.
  • To highlight aptamers targeting thrombin and other coagulation factors.
  • To discuss the potential of aptamers in clinical trials for anticoagulation.

Main Methods:

  • In-vitro selection (SELEX) to isolate aptamers from random oligonucleotide libraries.
  • Characterization of aptamer-target interactions and structural analysis.
  • Evaluation of aptamer efficacy and safety in preclinical and clinical studies.

Main Results:

  • Identification of aptamers targeting various coagulation proteins, with thrombin as a primary focus.
  • Demonstration of high specificity and affinity of aptamers for their targets.
  • Progression of several aptamer-based anticoagulants into clinical trials.

Conclusions:

  • Aptamers represent a novel class of therapeutic agents for anticoagulant therapy.
  • Continued research in aptamer design and evaluation is crucial for clinical translation.
  • Aptamers hold significant potential to overcome limitations of current anticoagulant drugs.